drugset / Trial / NCT04499950

Summary

This is a single arm phase II study designed to determine the effects of pharmacotherapy and a remote behavioral weight loss intervention on weight loss in breast cancer survivors who are overweight or obese, and the impact of successful weight loss on serum biomarkers and gut microbiome.

Timeline

Start
2021-02-08
Primary completion
2024-01-10
Completion
2024-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Contrave Unknown